Changeflow GovPing Healthcare & Life Sciences FDA DMB Acknowledges Lachman Consultant Service...
Routine Notice Added Final

FDA DMB Acknowledges Lachman Consultant Services Submission

Email

Summary

FDA's Division of Manufacturing and Budget (DMB) issued an acknowledgement letter to Lachman Consultant Services, Inc., confirming receipt of a submission filed under docket FDA-2026-P-4567. The acknowledgement was issued by CDER (Center for Drug Evaluation and Research). The actual letter content is available only as an attachment (attachment_1.pdf) and not displayed in the record page. No substantive regulatory action, deadline, or obligation is described in the visible document metadata.

Published by FDA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

Every FDA document on regulations.gov, the federal rulemaking portal. This is where the agency posts variances, advisory committee meeting notices, draft guidance for comment, citizen petition responses, and procedural rules that do not get a separate Federal Register slot. Around 240 a month. FDA's heavy regulations.gov use means tracking only the Federal Register misses a meaningful chunk of what the agency does day-to-day. Watch this if you manufacture devices, submit IND or NDA applications, run a lab, or advise sponsors on FDA process. GovPing publishes each posting with the docket, document type, division (CDER, CDRH, CFSAN), and comment window where one applies.

What changed

This record documents FDA's acknowledgement of a submission from Lachman Consultant Services, Inc. filed under FDA-2026-P-4567. The visible record contains only metadata: the issuing office (CDER/DMB), the attachment reference, and the acknowledgement status. No regulatory requirements, deadlines, or substantive determinations are visible in the page content itself.

Affected parties monitoring this docket for substantive FDA correspondence should download attachment_1.pdf to access the full acknowledgement letter. There are no compliance obligations created by this notice.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

There are no documents available to view or download

Attachments 1

Acknowledgement Letter from FDA DMB to Lachman Consultant Services, Inc.

More Information
- Author(s) CDER
Download

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Docket
FDA-2026-P-4567

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Regulatory submission Correspondence
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Topics
Healthcare

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!